Timber pharmaceuticals to highlight phase 2b control study results in multiple presentations at 31st eadv congress

- company announces positive clinical data of fda-designated breakthrough therapy tmb-001 demonstrating safety, efficacy and quality of life improvements in congenital ichthyosis patients will be presented in seven abstracts -
TMBR Ratings Summary
TMBR Quant Ranking